Skip to content
  • Debatforum
  • Seneste
  • Populære
  • Bruger
Temaer
  • Light
  • Dark

Kollaps
FORSIDEN
Log ind Opret konto

Genmab — Maj 2021

Planlagt Fastgjort Låst Flyttet Genmab
1.2k Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • BulderB Offline
    BulderB Offline
    Bulder
    wrote on sidst redigeret af
    #49

    Sponsors who obtain orphan designation benefit from protocol assistance, a type of scientific advice specific for designated orphan medicines, and market exclusivity once the medicine is on the market. Fee reductions are also available depending on the status of the sponsor and the type of service required. https://www.ema.europa.eu/en/human-regulatory/overview/orphan-designation-overview

    1 Reply Last reply
    0
    • BulderB Offline
      BulderB Offline
      Bulder
      wrote on sidst redigeret af
      #50

      The prevalence must not be more than 5 in 10.000, so they (Janssen) tried in vain to narrow it in.

      1 Reply Last reply
      0
      • BulderB Offline
        BulderB Offline
        Bulder
        wrote on sidst redigeret af
        #51

        As I see it "market exclusivity" is most important. A good thing to have of course, but not nescessary.

        1 Reply Last reply
        0
        • S Offline
          S Offline
          Sukkeralf
          wrote on sidst redigeret af
          #52

          Agree

          1 Reply Last reply
          0
          • S Offline
            S Offline
            Sukkeralf
            wrote on sidst redigeret af
            #53

            Here were it is the first indication they go after its almost of no importance

            1 Reply Last reply
            0
            • E Offline
              E Offline
              E_L
              wrote on sidst redigeret af
              #54

              i agree it is mainly about market exclusivity , but i do think that can be important with the rapid development of copy cats and generics. But i agree that it would only be for a small part of the market they may eventually target, as we know that they wouldn't get orphan for the whole NSCLC indication (if they decide to go for that broader label)

              1 Reply Last reply
              0
              • S Offline
                S Offline
                Sukkeralf
                wrote on sidst redigeret af
                #55

                Amgen saw two cases of peripheral polyneuropathy in a 42-subject study of its rival bispecific AMG 420. The BCMA bispecific is no longer featured in Amgen’s pipeline.

                1 Reply Last reply
                0
                • S Offline
                  S Offline
                  Sukkeralf
                  wrote on sidst redigeret af
                  #56

                  Just a moment...

                  favicon

                  (www.fiercebiotech.com)

                  1 Reply Last reply
                  0
                  • S Offline
                    S Offline
                    Sukkeralf
                    wrote on sidst redigeret af
                    #57

                    Anybody remember if Janssen saw peripheral polyneuropathy with thair BCMA/CD3 candidate

                    1 Reply Last reply
                    0
                    • BulderB Offline
                      BulderB Offline
                      Bulder
                      wrote on sidst redigeret af
                      #58

                      https://www.businesswire.com/news/home/20201205005041/en/Updated-Results-from-the-Phase-1-Study-of-the-BCMAxCD3-Bispecific-Teclistamab-Show-Preliminary-Efficacy-in-Patients-with-Heavily-Pretreated-Relapsed-or-Refractory-Multiple-Myeloma

                      1 Reply Last reply
                      0
                      • BulderB Offline
                        BulderB Offline
                        Bulder
                        wrote on sidst redigeret af
                        #59

                        Ikke så vidt jeg kunne se

                        1 Reply Last reply
                        0
                        • Helge_LarsenPI-redaktørH Offline
                          Helge_LarsenPI-redaktørH Offline
                          Helge_LarsenPI-redaktør
                          wrote on sidst redigeret af
                          #60

                          Go morgen. 🙂

                          1 Reply Last reply
                          0
                          • Helge_LarsenPI-redaktørH Offline
                            Helge_LarsenPI-redaktørH Offline
                            Helge_LarsenPI-redaktør
                            wrote on sidst redigeret af
                            #61

                            Onsdagens aviser med Pandora, Jyske Bank og Huscompaniet https://www.proinvestor.com/investornyt/674730/onsdagens-aviser-med-pandora-jyske-bank-og-huscompaniet

                            1 Reply Last reply
                            0
                            • Helge_LarsenPI-redaktørH Offline
                              Helge_LarsenPI-redaktørH Offline
                              Helge_LarsenPI-redaktør
                              wrote on sidst redigeret af
                              #62

                              Yellen hverken forudså eller anbefalede renteforhøjelser - GENT https://www.proinvestor.com/investornyt/674728/yellen-hverken-forudsa-eller-anbefalede-renteforhojelser-gent

                              1 Reply Last reply
                              0
                              • E Offline
                                E Offline
                                E_L
                                wrote on sidst redigeret af
                                #63

                                AMG 420 was halted a while back and is followed by AMG 701. but that wasn't going flawless either: AMG 701 Enrollment in the Phase 1 study has been paused while we discuss protocol modifications to optimize safety monitoring and mitigation with the FDA. Currently enrolled patients who are demonstrating benefit may continue to receive investigational product and the Company expects to resume patient enrollment in H1 2021

                                1 Reply Last reply
                                0
                                • E Offline
                                  E Offline
                                  E_L
                                  wrote on sidst redigeret af
                                  #64

                                  i also recently saw some BCMA ADC's being stopped, one of them might have been Amgen also, can't remember

                                  1 Reply Last reply
                                  0
                                  • E Offline
                                    E Offline
                                    E_L
                                    wrote on sidst redigeret af
                                    #65

                                    Positive results for this proof-of-concept, pilot study to evaluate the safety and efficacy of daratumumab in patients with PGNMID, a disease for which there is no standard of care. :

                                    1 Reply Last reply
                                    0
                                    • E Offline
                                      E Offline
                                      E_L
                                      wrote on sidst redigeret af
                                      #66

                                      Safety and Efficacy of Daratumumab in Patients with Proliferative GN with Monoclonal Immunoglobulin Deposits https://jasn.asnjournals.org/content/32/5/1163

                                      1 Reply Last reply
                                      0
                                      • B Offline
                                        B Offline
                                        Biocopper
                                        wrote on sidst redigeret af
                                        #67

                                        Godmorgen, hvornår bliver regnskabet offentliggjort?

                                        1 Reply Last reply
                                        0
                                        • B Offline
                                          B Offline
                                          Biocopper
                                          wrote on sidst redigeret af
                                          #68

                                          Tak Pensionisten, her tror jeg ellers det skulle være om morgenen så det ikke skete i åbningstiden i USA 🙂

                                          1 Reply Last reply
                                          0

                                          Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                          Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                          With your input, this post could be even better 💗

                                          Tilmeld Log ind

                                          • Log ind

                                          • Har du ikke en konto? Tilmeld

                                          • Login or register to search.
                                          • First post
                                            Last post
                                          0
                                          • Debatforum
                                          • Seneste
                                          • Populære
                                          • Bruger